FLECAINID ACETAT - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

flecain flecainide acetate 100mg tablet blister pack

micro labs pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: silicified microcrystalline cellulose; croscarmellose sodium; magnesium stearate; maize starch - flecain is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecain should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecain tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

flecar flecainide acetate 50 mg tablet blister pack

micro labs pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: maize starch; magnesium stearate; silicified microcrystalline cellulose; croscarmellose sodium - flecar is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecar should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecar tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

flecar flecainide acetate 100 mg tablet blister pack

micro labs pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; silicified microcrystalline cellulose; maize starch - flecar is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecar should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecar tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

flec-em flecainide acetate 100 mg tablet blister pack

emcure pharmaceuticals pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate - flec-em is indicated for:,1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes b) due to dual av nodal pathways in patients with debilitating symptoms c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flec-em may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flec-em should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flec-em in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs. flec-em tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous (available in other brands) therapy or conversion by other means.

Australia - English - Department of Health (Therapeutic Goods Administration)

flec-em flecainide acetate 50 mg tablet blister pack

emcure pharmaceuticals pty ltd - flecainide acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate - flec-em is indicated for:,1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes b) due to dual av nodal pathways in patients with debilitating symptoms c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flec-em may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flec-em should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flec-em in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs. flec-em tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous (available in other brands) therapy or conversion by other means.